1. Home
  2. POET vs XNCR Comparison

POET vs XNCR Comparison

Compare POET & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POET Technologies Inc.

POET

POET Technologies Inc.

HOLD

Current Price

$6.27

Market Cap

775.8M

Sector

Technology

ML Signal

HOLD

Logo Xencor Inc.

XNCR

Xencor Inc.

HOLD

Current Price

$12.29

Market Cap

881.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POET
XNCR
Founded
1972
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
775.8M
881.9M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
POET
XNCR
Price
$6.27
$12.29
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$22.33
AVG Volume (30 Days)
8.7M
793.3K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.36
EPS
N/A
N/A
Revenue
N/A
$125,576,000.00
Revenue This Year
$848.96
N/A
Revenue Next Year
$700.00
$4.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.65
52 Week Low
$3.53
$6.92
52 Week High
$9.41
$18.69

Technical Indicators

Market Signals
Indicator
POET
XNCR
Relative Strength Index (RSI) 52.46 52.24
Support Level $6.00 $12.29
Resistance Level $7.31 $12.87
Average True Range (ATR) 0.48 0.81
MACD 0.03 0.07
Stochastic Oscillator 87.07 61.61

Price Performance

Historical Comparison
POET
XNCR

About POET POET Technologies Inc.

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Share on Social Networks: